Clinical Webinar Series on Anesthesia and Medicine

This series includes two one-hour webinars:

Sedation for the Chronic Marijuana User on July 12 at 6 p.m. CT

Psychedelics in Oral and Maxillofacial Surgery on July 26 at 6 p.m. CT

  • Contains 5 Component(s), Includes Credits Includes a Live Web Event on 07/12/2023 at 6:00 PM (CDT)

    Cannabis is the most popular illicit drug worldwide. While the DEA still classifies it as a Schedule I controlled substance, it is now legal in many states – with cannabis use still on the rise in the U.S. This increase is particularly seen in high school and college-age students. OMSs will likely encounter patients who use cannabis, affecting the administration and effects of anesthesia – including local anesthesia, nitrous oxide and intravenous sedation/anesthesia. It is important for OMSs to understand how to manage patients who use cannabis. During this 60-minute webinar, participants will learn the pharmacologic and physiologic effects of cannabis, different intake methods and how cannabis can affect office-based anesthesia. Code: WCE230712

    image

    Sedation for the Chronic Marijuana User

    Cannabis is the most popular illicit drug worldwide. While the DEA still classifies it as a Schedule I controlled substance, it is now legal in many states – with cannabis use still on the rise in the U.S. This increase is particularly seen in high school and college-age students. OMSs will likely encounter patients who use cannabis, affecting the administration and effects of anesthesia – including local anesthesia, nitrous oxide and intravenous sedation/anesthesia. It is important for OMSs to understand how to manage patients who use cannabis. During this 60-minute webinar, participants will learn the pharmacologic and physiologic effects of cannabis, different intake methods and how cannabis can affect office-based anesthesia.

    Learning Objectives

    At the conclusion of this program, participants should be able to:

    1. Explain the different forms of cannabis intake. 
    2. Describe the pharmacologic and physiologic effects of cannabis. 
    3. Identify special considerations of orthognathic surgery in the cleft lip and palate patient.  
    4. Discuss how marijuana use affects office-based anesthesia.

    Cancellation Policy: Registrants will receive a full refund up until the day before the event. No refund will be given on the day of or after the event. 

    Register for the two-part Clinical Webinar Series on Anesthesia and Medicine and save $50 off the original price of $250!

    Kathlyn Powell, DMD, MD

    Kathlyn Powell, DMD, MD, graduated from the University of Alabama at Birmingham School of Dentistry, where she also completed her residency in oral and maxillofacial surgery. She completed a pediatric oral and maxillofacial surgery fellowship at the University of Alabama at Birmingham and the Children’s of Alabama Hospital. Assuming a full-time position at the University of Alabama at Birmingham Department of Oral and Maxillofacial Surgery, Dr. Powell also became the first full time OMS at Children’s of Alabama Hospital. Dr. Powell is residency program director.

    She is board-certified and serves as a Board Examiner for ABOMS. Dr. Powell has an academic/hospital-based practice and is a member of numerous professional organizations, including AAOMS and the Southeastern Society of Oral and Maxillofacial Surgeons.

    Disclosures: No relevant financial relationships were disclosed.

    Continuing Education Provider Approval
    The American Association of Oral and Maxillofacial Surgeons is an ADA CERP Recognized Provider.

    ADA CERP is a service of the American Dental Association to assist dental professionals in identifying quality providers of continuing dental education.

    ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of credit hours by boards of dentistry.

    The American Association of Oral and Maxillofacial Surgeons designates this activity for 1.0 continuing education credit(s).

    AGD - Accepted Program Provider
    FAGD/MAGD Credit
    11/1/22-12/31/26
    Provider ID# 214680

    The American Association of Oral and Maxillofacial Surgeons (AAOMS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The American Association of Oral and Maxillofacial Surgeons designates this internet-based live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Contains 5 Component(s), Includes Credits Includes a Live Web Event on 07/26/2023 at 2:15 PM (CDT)

    In recent years, there has been a growing interest in the use of psychedelic substances as a potential treatment option for a variety of medical conditions. Regulatory restrictions on research into psychedelics were lifted in 2000, and the first landmark study on psilocybin at Johns Hopkins University was published in 2006. The volume of research has been growing every year. Psychedelics such as psilocybin, lysergic acid diethylamide (LSD) and methylenedioxymethamphetamine (MDMA) have been shown in clinical trials to be effective in treating conditions such as depression, anxiety, PTSD, addiction and end-of-life distress. In recent years, several cities such as Detroit, Seattle and Santa Cruz as well as all of Oregon and Colorado have decriminalized the possession and use of psychedelic substances. The FDA has granted breakthrough therapy designation for psilocybin and MDMA-assisted therapy for certain conditions. As legislation changes and psychedelics move from the underground to the mainstream, the anesthetic, dental and oral and maxillofacial surgery fields will have to adjust. This 60-minute webinar will define psychedelics and explore the risks, benefits and potential place in dentistry and oral and maxillofacial surgery. Code: WCE230726

    image

    Psychedelics in Oral and Maxillofacial Surgery

    In recent years, there has been a growing interest in the use of psychedelic substances as a potential treatment option for a variety of medical conditions. Regulatory restrictions on research into psychedelics were lifted in 2000, and the first landmark study on psilocybin at Johns Hopkins University was published in 2006. The volume of research has been growing every year. Psychedelics such as psilocybin, lysergic acid diethylamide (LSD) and methylenedioxymethamphetamine (MDMA) have been shown in clinical trials to be effective in treating conditions such as depression, anxiety, PTSD, addiction and end-of-life distress. In recent years, several cities such as Detroit, Seattle and Santa Cruz as well as all of Oregon and Colorado have decriminalized the possession and use of psychedelic substances. The FDA has granted breakthrough therapy designation for psilocybin and MDMA-assisted therapy for certain conditions. As legislation changes and psychedelics move from the underground to the mainstream, the anesthetic, dental and oral and maxillofacial surgery fields will have to adjust. This 60-minute webinar will define psychedelics and explore the risks, benefits and potential place in dentistry and oral and maxillofacial surgery.

    Learning Objectives

    At the conclusion of this program, participants should be able to:

    1. Identify the most common types of psychedelics used by patients.  
    2. Describe non-ordinary states of consciousness. 
    3. Analyze the potential of psychedelics for anxiety management. 
    4. Apply knowledge of psychedelics into clinical practice with regard to surgery and anesthesia.

    Cancellation Policy: Registrants will receive a full refund up until the day before the event. No refund will be given on the day of or after the event. 

    Register for the two-part Clinical Webinar Series on Anesthesia and Medicine and save $50 off the original price of $250!

    Edna Buckle, DDS

    Edna Buckle, DDS, was born in Ghana and grew up primarily in Michigan. She completed her dental training at the University Of Maryland. She is currently an anesthesia evaluator for the Maryland State Dental Association and visits other offices to verify that they are prepared to safely perform sedation on patients.After dental school, Dr. Buckle completed four years of oral and maxillofacial surgery training at Howard University Hospital in Washington, D.C., with an emphasis on trauma and maxillofacial surgery as well as extractions, pathology, sedation and management of medically compromised patients. Dr. Buckle is an ABOMS Diplomate and a member of AAOMS, the Mid-Atlantic Society of Oral and Maxillofacial Surgeons, the International Affiliation of Tongue Tie Professionals and the Holistic Dental Association.

    Disclosures: No relevant financial relationships were disclosed.

    Continuing Education Provider Approval
    The American Association of Oral and Maxillofacial Surgeons is an ADA CERP Recognized Provider.

    ADA CERP is a service of the American Dental Association to assist dental professionals in identifying quality providers of continuing dental education.

    ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of credit hours by boards of dentistry.

    The American Association of Oral and Maxillofacial Surgeons designates this activity for 1.0 continuing education credit(s).

    AGD - Accepted Program Provider
    FAGD/MAGD Credit
    11/1/22-12/31/26
    Provider ID# 214680

    The American Association of Oral and Maxillofacial Surgeons (AAOMS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The American Association of Oral and Maxillofacial Surgeons designates this internet-based live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.